Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Market Cap | 197.09M +76.1% |
| Revenue (ttm) | n/a |
| Net Income | -101.90M |
| EPS | -6.09 |
| Shares Out | 19.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 407,268 |
| Open | 9.97 |
| Previous Close | 9.84 |
| Day's Range | 9.90 - 10.38 |
| 52-Week Range | 7.12 - 20.56 |
| Beta | 2.62 |
| Analysts | Strong Buy |
| Price Target | 34.53 (+238.86%) |
| Earnings Date | Aug 6, 2026 |
About CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for CRBP stock is "Strong Buy." The 12-month stock price target is $34.53, which is an increase of 238.86% from the latest price.
News
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the g...
Corbus Pharmaceuticals Holdings Earnings release: Q2 2026
Corbus Pharmaceuticals Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Corbus Pharmaceuticals Holdings Quarterly report: Q2 2026
Corbus Pharmaceuticals Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1 ...
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patient...
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapi...
Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026
Two lead clinical assets are advancing: CRB-701 shows strong efficacy in HPV-positive oropharyngeal and cervical cancers, with pivotal studies aligned with FDA and a significant U.S. market opportunity. CRB-913 obesity data is expected in September, and cash runway extends into 2028.
Corbus Pharmaceuticals Holdings Slides: FY 2026
Corbus Pharmaceuticals Holdings has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 4, 2026.
Corbus Pharmaceuticals Holdings Transcript: KOL event
Panelists highlighted the rising incidence and unmet need in HPV-positive oropharyngeal cancer, emphasizing the promise of Nectin-4 ADCs like CRB-701 for this motivated patient group. Strategic trial design, manageable toxicity, and focused site selection are expected to drive rapid enrollment and strong clinical impact.
Corbus Pharmaceuticals Holdings Transcript: Study update
Updated ASCO data show strong efficacy and safety for CRB-701 in oropharyngeal head and neck and cervical cancers, with a 43% ORR in oropharyngeal and 34% in cervical at the top dose. Ocular toxicity is manageable, and the phase III TEMPO-1 trial will focus on oropharyngeal patients.
Corbus Pharmaceuticals Holdings Press release: Study update
Corbus Pharmaceuticals Holdings issued a press release on May 26, 2026, disclosing material business information to investors.
Corbus Pharmaceuticals Holdings Slides: Study update
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study (NCT0626...
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals Holdings Transcript: RBC Capital Markets Global Healthcare Conference 2026
Upcoming ASCO presentations will provide mature efficacy and safety data for CRB-701 in cervical and head and neck cancers, guiding regulatory and clinical strategies. The obesity program CRB-913 has completed enrollment, with late summer data expected to clarify its competitive potential.
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals Holdings Slides: Corporate presentation
Corbus Pharmaceuticals Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Corbus Pharmaceuticals Holdings Transcript: AGM 2026
The meeting covered director elections, an equity plan amendment, auditor ratification, and advisory votes on executive compensation and its voting frequency. All proposals passed by majority or plurality, with final results to be filed in a Form 8-K. No shareholder questions were raised.
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t...
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new therapie...
Corbus Pharmaceuticals Holdings Earnings release: Q1 2026
Corbus Pharmaceuticals Holdings released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Corbus Pharmaceuticals Holdings Quarterly report: Q1 2026
Corbus Pharmaceuticals Holdings has published its Q1 2026 quarterly earnings report on May 12, 2026.
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announ...
Corbus Pharmaceuticals Holdings Proxy statement: Proxy filing
Corbus Pharmaceuticals Holdings filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.